Surveillance of gd T cells predicts cytomegalovirus infection resolution in kidney transplants

Journal of the American Society of Nephrology

Volumn 27, Issue 2, 2016, Pages 637-645

  Kaminski, Hannah ^a   Garrigue, Isabelle ^b,c   Couzi, Lionel ^a,c   Taton, Benjamin ^a   Bachelet, Thomas ^a,c   Moreau, Jean François ^a,c   Déchanet Merville, Julie ^c   Thiébaut, Rodolphe ^d,e   Merville, Pierre ^a,c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b University Victor Segalen   (France)

^c CNRS   (France)

^d INSERM   (France)

^e INRIA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; FEMALE; GAMMA DELTA T LYMPHOCYTE; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; VIRUS LOAD; BLOOD; CYTOMEGALOVIRUS INFECTIONS; IMMUNOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REMISSION; T LYMPHOCYTE; VIROLOGY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REMISSION INDUCTION; T-LYMPHOCYTES;

EID: 84970935475     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014100985     Document Type: Article

References (40)

1. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A; Transplantation Society International CMV Consensus Group: Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96: 333-360, 2013
2. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; VICTOR Study Group: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7: 2106-2113, 2007
3. Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, Bignamini A, Töz H, Dittmer I, Montejo M, Hartmann A; VICTOR Study Group: Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. AmJ Transplant 9: 1205-1213, 2009
4. Le Page AK, JagerMM, Iwasenko JM, ScottGM, Alain S, Rawlinson WD: Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 56: 1018-1029, 2013
5. Emery VC, Griffiths PD: Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 97: 8039-8044, 2000
6. Hantz S,Garnier-Geoffroy F,MazeronMC,Garrigue I,Merville P,Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germi R, Pillet S, Lebranchu Y, Turlure P, Alain S; French CMV Resistance Survey Study Group: Drug-resistant cytomegalovirus in transplant recipients: A French cohort study. J Antimicrob Chemother 65: 2628-2640, 2010
7. Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A: Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 14: 697-704, 2009
8. Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A,Hartmann A: Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 92: 217-223, 2011
9. Egli A, Humar A, Kumar D: State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: A primer for the clinician. Clin Infect Dis 55: 1678-1689, 2012
10. Patel M, Stefanidou M, Long CB, FazzariMJ, Tesfa L, Del RioM, Lamour J, Ricafort R, Madan RP, Herold BC:Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant 16: 18-28, 2012
11. Pipeling MR, John ER, Orens JB, Lechtzin N, McDyer JF: Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J Infect Dis 204: 1663-1671, 2011
12. ChiereghinA,Gabrielli L, Zanfi C,Petrisli E, LauroA,PiccirilliG,Baccolini F, Dazzi A, Cescon M, Morelli MC, Pinna AD, Landini MP, Lazzarotto T: Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. Transplant Proc 42: 69-73, 2010
13. Déchanet J,Merville P, Bergé F, Bone-Mane G, Taupin JL,Michel P, Joly P, Bonneville M, Potaux L, Moreau JF: Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J Infect Dis 179: 1-8, 1999
14. Knight A,Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P, Mackinnon S, Travers PJ, Lowdell MW: The role of Vd2-negative gd T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 116: 2164-2172, 2010
15. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, Van Rysselberge M, Twité N, Goldman M, Marchant A, Willems F: Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. J ExpMed 207: 807-821, 2010
16. Pitard V, RoumanesD, Lafarge X,Couzi L,Garrigue I, LafonME,Merville P, Moreau JF, Déchanet-Merville J: Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection. Blood 112: 1317-1324, 2008
17. Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O, Merville P, Moreau JF, Déchanet-Merville J: Antibody-dependent anti-cytomegalovirus activity of human gd T cells expressingCD16 (FcgRIIIa). Blood 119: 1418-1427, 2012
18. Halary F, PitardV,DlubekD,Krzysiek R,dela Salle H,Merville P, Dromer C, Emilie D, Moreau JF, Déchanet-Merville J: Shared reactivity of Vdelta2 (neg) gammadelta T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J ExpMed 201: 1567-1578, 2005
19. Couzi L,Helou S, Bachelet T, MoreauK, Martin S,MorelD, LafonME, Boyer B, Alain S, Garrigue I, Merville P: High incidence of anticytomegalovirusdrugresistance amongD+R-kidney transplant recipients receiving preemptive therapy. Am J Transplant 12: 202-209, 2012
20. Cantisán S, Lara R, Montejo M, Redel J, Rodríguez-Benot A, Gutiérrez-Aroca J, González-Padilla M, Bueno L, Rivero A, Solana R, Torre-Cisneros J: Pretransplant interferon-g secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant 13: 738-745, 2013
21. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A: Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 9: 1214-1222, 2009
22. Lisboa LF, Kumar D, Wilson LE, Humar A: Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 93: 195-200, 2012
23. Martín-Gandul C, Pérez-Romero P, Blanco-Lobo P, Benmarzouk-Hidalgo OJ, Sánchez M, Gentil MA, Bernal C, Sobrino JM, Rodríguez-Hernández MJ, Cordero E; Spanish Network for Research in Infectious Diseases (REIPI): Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy. Transpl Int 27: 1060-1068, 2014
24. Sester M, Sester U, Gärtner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Köhler H: Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71: 1287-1294, 2001
25. Egli A, Silva M Jr. , O'Shea D, Wilson LE, Baluch A, Lisboa LF, Hidalgo LG, Kumar D, Humar A: An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS ONE 7: e43937, 2012
26. EgliA, Binet I, Binggeli S, JägerC,DumoulinA, SchaubS, Steiger J, Sester U, Sester M, Hirsch HH: Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 6: 29, 2008
27. Abate D, Saldan A, Forner G, Tinto D, Bianchin A, Palù G: Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants. J Virol Methods 196: 157-162, 2014
28. Westall GP,MifsudNA, Kotsimbos T: Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMVspecific CD8+ T-cell immunity. Am J Transplant 8: 1749-1754, 2008
29. Vantourout P, Hayday A: Six-of-the-best: Unique contributions of gd T cells to immunology. Nat Rev Immunol 13: 88-100, 2013
30. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6: 2134-2143, 2006
31. Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V: Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 8: 69-77, 2008
32. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR:Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 46: 840-846, 2008
33. Limaye AP: Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 35: 866-872, 2002
34. La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey SF, Limaye AP, Diamond DJ: Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 197: 25-33, 2008
35. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, EichbaumQ, Altfeld M,Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354, 2006
36. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM: Expanded criteria donors for kidney transplantation. Am J Transplant 3 [Suppl 4]: 114-125, 2003
37. KoningOH, Ploeg RJ, van Bockel JH, GroenewegenM, van derWoude FJ, Persijn GG, Hermans J; European Multicenter Study Group: Risk factors for delayed graft function in cadaveric kidney transplantation: A prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. Transplantation 63: 1620-1628, 1997
38. Garrigue I, Doussau A, Asselineau J, Bricout H, Couzi L, Rio C, Merville P, Fleury H, LafonME, Thiébaut R: Prediction of cytomegalovirus (CMV) plasma load fromevaluation of CMV whole-blood load in samples from renal transplant recipients. J Clin Microbiol 46: 493-498, 2008
39. Chou S, Marousek G, Boivin G, Goyette N, FarhanM, Ives JA, Elston R: Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 90: 1409-1413, 2010
40. Team RCR: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2012. Available at: http://www. R-project. org/. Accessed March 31, 2013